Erythropoietin gene therapy - Valentis

Drug Profile

Erythropoietin gene therapy - Valentis

Alternative Names: EPO/Switch; EpoSwitch; EpoSwitch GeneMedicine

Latest Information Update: 19 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valentis
  • Class Antianaemics; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 19 Sep 2008 Updated MoA
  • 24 May 2001 Erythropoietin gene therapy in combination with EPOSwitchTM is available for licensing (http://www.valentis.com/)
  • 06 Jun 2000 Preclinical development for Anaemia in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top